HRP20080307T3 - Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove - Google Patents
Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekoveInfo
- Publication number
- HRP20080307T3 HRP20080307T3 HR20080307T HRP20080307T HRP20080307T3 HR P20080307 T3 HRP20080307 T3 HR P20080307T3 HR 20080307 T HR20080307 T HR 20080307T HR P20080307 T HRP20080307 T HR P20080307T HR P20080307 T3 HRP20080307 T3 HR P20080307T3
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- hydroxy
- hydrogen
- het
- halo
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- -1 cyano, hydroxy Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 2
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 241000186359 Mycobacterium Species 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uporaba supstituiranog kinolinskog derivata, naznačena time, da se derivat rabi za proizvodnju lijeka za tretman infekcije sojem Mycobacterium koji je otporan na lijek, a gdje supstituirani kinolinski derivat je spoj sukladno Formuli (Ia) ili Formuli (Ib) (Ia) (Ib) ili njegova farmaceutski prihvatljiva kiselinska ili bazna adicijska sol, stereokemijski izomerni oblik, tautomerni oblik ili N-oksid, gdje: R1 je vodik, halo, haloalkil, cijano, hidroksi, Ar, Het, alkil, alkoksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; p je cijeli broj jednak 1, 2, 3 ili 4; R2 je vodik, hidroksi, merkapto, alkiloksi, alkiloksialkiloksi,alkiltio, mono ili di(alkil)amino ili radikal s formulomgdje Y je CH2, O, S, NH ili N-alkil; R3 je alkil, Ar, Ar-alkil, Het ili Het-alkil; q je cijeli broj jednak ništici, 1, 2, 3 ili 4; R4 i R5 svaki neovisno je vodik, alkil ili benzil; iliR4 i R5 skupa te uključujući i N kome su pripojeni, mogu oblikovati radikal izabran iz skupine koja se sastoji od pirolidinila, 2H-pirolila, 2-pirolinila, 3-pirolinila, pirolila, imidazolidinila, pirazolidinila, 2-imidazolinila, 2-pirazolinila, imidazolila, pirazolila, tiazolila, piperidinila, piridinila, piperazinila, imidazolidinila, piridazinila, pirimidinila, pirazinila, triazinila, morfolinila i tiomorfolinila, ponekad supstituiran s alkilom, halo, haloalkilom, hidroksi, alkiloksi, amino, mono ili dialkilamino, alkiltio, alkiloksialkilom, alkiltioalkilom i pirimidinilom; R6 je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ilidva susjedna R6 radikala mogu biti uzeta skupa da bi oblikovali dvovalentan radikal s formulom -CH=CH-CH=CH-; r je cijeli broj jednak 1, 2, 3, 4 ili 5; iR7 je vodik, alkil, Ar ili Het; R8 je vodik ili alkil; R9 je okso; iliR8 i R9 skupa oblikuju radikal =N-CH=CH-;alkil je ravnolančani ili razgranati zasićeni ugljikovodični radikal koji posjeduje od 1 do 6 ugljikovih atoma; ili predstavlja prstenasti zasićeni ugljikovodični radikal koji imaod 3 do 6 ugljikova atoma; ili predstavlja prstenasti zasićeni ugljikovodični radikal koji ima od 3do 6 ugljikovih atoma spojenih na ravnolančani ili razgranati zasićeni ugljikovodični radikal koji ima od 1 do 6 ugljikovih atoma; gdje svaki ugljikov atom može biti ponekad supstituiran s halo, hidroksi, alkiloksi ili okso; Ar je homoprsten izabraniz skupine koja obuhvaća fenil, naftil, acenaftil, tetrahidronaftil, svaki ponekad supstituiran s 1, 2 ili 3 supstituenta, a svaki supstituent je neovisno izabran iz skupine koja obuhvaća hidroksi, halo, cijano, nitro, amino, mono ili dialkilamino, alkil, haloalkil, alkiloksi, haloalkiloksi, karbonil, alkiloksikarbonil, aminokarbonil, morfolinil imono ili dalkilaminokarbonil; Het je monoprsten izabran iz skupine koja obuhvaća N-fenoksipiperidinil, pirolil, pirazolil, imidazolil, furanil, tienil, oksazolil, izooksazolil, tiazolil, izotiazolil,piridinil, pirimidinil, pirazinil i piridazinil; ili bip
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102402 | 2004-05-28 | ||
| PCT/EP2005/052371 WO2005117875A1 (en) | 2004-05-28 | 2005-05-24 | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080307T3 true HRP20080307T3 (hr) | 2008-07-31 |
Family
ID=34929150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080307T HRP20080307T3 (hr) | 2004-05-28 | 2008-06-30 | Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20070249667A1 (hr) |
| EP (1) | EP1753427B1 (hr) |
| JP (2) | JP5081617B2 (hr) |
| KR (2) | KR101371653B1 (hr) |
| CN (2) | CN102908347A (hr) |
| AP (1) | AP2037A (hr) |
| AR (1) | AR049127A1 (hr) |
| AT (1) | ATE390925T1 (hr) |
| AU (1) | AU2005249231B2 (hr) |
| BR (1) | BRPI0510414B1 (hr) |
| CA (1) | CA2566544C (hr) |
| CL (1) | CL2009001980A1 (hr) |
| CY (1) | CY1110388T1 (hr) |
| DE (1) | DE602005005810T2 (hr) |
| DK (1) | DK1753427T3 (hr) |
| EA (1) | EA010651B1 (hr) |
| ES (1) | ES2306146T3 (hr) |
| HK (1) | HK1106136A1 (hr) |
| HR (1) | HRP20080307T3 (hr) |
| IL (1) | IL179630A (hr) |
| JO (1) | JO2524B1 (hr) |
| ME (1) | ME01105B (hr) |
| MX (1) | MXPA06013888A (hr) |
| MY (1) | MY140611A (hr) |
| NO (1) | NO338624B1 (hr) |
| NZ (1) | NZ550840A (hr) |
| PA (1) | PA8635201A1 (hr) |
| PL (1) | PL1753427T3 (hr) |
| PT (1) | PT1753427E (hr) |
| RS (1) | RS50585B (hr) |
| SI (1) | SI1753427T1 (hr) |
| TW (1) | TWI363625B (hr) |
| UA (1) | UA90267C2 (hr) |
| WO (1) | WO2005117875A1 (hr) |
| ZA (1) | ZA200609899B (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| KR101301573B1 (ko) * | 2004-12-24 | 2013-09-04 | 얀센 파마슈티카 엔.브이. | 잠재성 튜버큐로시스의 치료법 |
| CA2528849C (en) | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| JP5349730B2 (ja) * | 2005-06-09 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としてのキノリン誘導体 |
| BRPI0613999B8 (pt) * | 2005-06-28 | 2021-05-25 | Janssen Pharmaceutica Nv | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto |
| JO3270B1 (ar) * | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
| JO2752B1 (en) * | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| EP1917245A1 (de) | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO3271B1 (ar) | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2725B1 (en) * | 2006-12-06 | 2013-09-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2684B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| JO2685B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
| JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| MD4009C2 (ro) * | 2008-07-15 | 2010-08-31 | Институт Химии Академии Наук Молдовы | Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos |
| RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
| CN102655865A (zh) * | 2009-09-11 | 2012-09-05 | 沃泰克斯药物股份有限公司 | N-苄基-3-(4-氯苯基)-2-[甲基-[2-氧代-2-(3,4,5-三甲氧基苯基)乙酰基]氨基]-n-[3-(4-吡啶基)-1-[2-(4-吡啶基)乙基]丙酰胺的组合物及其用途 |
| CN102249935B (zh) * | 2010-05-17 | 2015-05-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳香2-丁醇类化合物及其医药用途 |
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| EA038350B1 (ru) | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
| BR112017000764B1 (pt) * | 2014-07-14 | 2022-07-12 | Shanghai Jia Tan Pharmatech Co. Ltd. | Composto, método para preparar o composto e uso do composto |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| AU2016212116B2 (en) * | 2015-01-27 | 2021-07-15 | Janssen Pharmaceutica Nv | Dispersible compositions |
| CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
| EP3366676B1 (en) | 2015-10-20 | 2021-05-26 | Zhejiang Hisun Pharmaceutical Co., Ltd | Crystalline forms of bedaquiline fumarate and preparation methods therefor |
| WO2017121323A1 (zh) * | 2016-01-13 | 2017-07-20 | 辰欣药业股份有限公司 | 一种吡啶衍生物类化合物的制备方法及其中间体和晶型 |
| US10508097B2 (en) * | 2016-03-07 | 2019-12-17 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| CN107243008B (zh) * | 2017-04-13 | 2021-03-30 | 中国科学院广州生物医药与健康研究院 | 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物 |
| CN111278985B (zh) * | 2017-09-01 | 2023-09-08 | 学校法人北里研究所 | 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法 |
| WO2020047596A1 (en) * | 2018-09-04 | 2020-03-12 | Monash University | Antibacterial compounds and methods of use |
| JP2022516671A (ja) | 2019-01-09 | 2022-03-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 非結核性抗酸菌症の処置における組合せ |
| WO2021107876A1 (en) * | 2019-11-26 | 2021-06-03 | Nanyang Technological University | Compounds for treating tuberculosis |
| CN110804016B (zh) * | 2019-12-05 | 2022-11-04 | 福建省微生物研究所 | 抗结核分枝杆菌的二芳基喹啉衍生物 |
| CN116406270A (zh) | 2020-11-12 | 2023-07-07 | 詹森药业有限公司 | 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合 |
| CN117050006A (zh) * | 2022-05-13 | 2023-11-14 | 广州嘉越医药科技有限公司 | 一种吡啶衍生物、中间体、制备方法和应用 |
| WO2023227123A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州嘉越医药科技有限公司 | 吡啶衍生物的用途 |
| WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399558A (en) * | 1993-11-24 | 1995-03-21 | Pathogenesis Corporation | Isoflavonoid antibacterial compounds, compositions and use |
| CA2270123A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| PL222801B1 (pl) * | 2002-07-25 | 2016-09-30 | Janssen Pharmaceutica Nv | Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
-
2005
- 2005-05-24 EP EP05743054A patent/EP1753427B1/en active Active
- 2005-05-24 CN CN2012103943126A patent/CN102908347A/zh active Pending
- 2005-05-24 US US11/569,681 patent/US20070249667A1/en not_active Abandoned
- 2005-05-24 AU AU2005249231A patent/AU2005249231B2/en active Active
- 2005-05-24 DE DE602005005810T patent/DE602005005810T2/de active Active
- 2005-05-24 KR KR1020067024974A patent/KR101371653B1/ko active Protection Beyond IP Right Term
- 2005-05-24 EA EA200602260A patent/EA010651B1/ru active Protection Beyond IP Right Term
- 2005-05-24 DK DK05743054T patent/DK1753427T3/da active
- 2005-05-24 AT AT05743054T patent/ATE390925T1/de active
- 2005-05-24 ES ES05743054T patent/ES2306146T3/es active Active
- 2005-05-24 PT PT05743054T patent/PT1753427E/pt unknown
- 2005-05-24 NZ NZ550840A patent/NZ550840A/en unknown
- 2005-05-24 CA CA2566544A patent/CA2566544C/en active Active
- 2005-05-24 BR BRPI0510414-9A patent/BRPI0510414B1/pt active IP Right Grant
- 2005-05-24 ME MEP-2008-89A patent/ME01105B/me unknown
- 2005-05-24 JO JO200574A patent/JO2524B1/en active
- 2005-05-24 MX MXPA06013888A patent/MXPA06013888A/es active IP Right Grant
- 2005-05-24 KR KR1020137002606A patent/KR20130024969A/ko not_active Application Discontinuation
- 2005-05-24 RS RSP-2008/0291A patent/RS50585B/sr unknown
- 2005-05-24 AP AP2006003828A patent/AP2037A/xx active
- 2005-05-24 PL PL05743054T patent/PL1753427T3/pl unknown
- 2005-05-24 UA UAA200611048A patent/UA90267C2/ru unknown
- 2005-05-24 SI SI200530294T patent/SI1753427T1/sl unknown
- 2005-05-24 JP JP2007513922A patent/JP5081617B2/ja active Active
- 2005-05-24 WO PCT/EP2005/052371 patent/WO2005117875A1/en active Application Filing
- 2005-05-24 CN CN2005800170162A patent/CN1976704B/zh active Active
- 2005-05-27 AR ARP050102200A patent/AR049127A1/es unknown
- 2005-05-27 PA PA20058635201A patent/PA8635201A1/es unknown
- 2005-05-27 TW TW094117334A patent/TWI363625B/zh active
- 2005-05-27 MY MYPI20052432A patent/MY140611A/en unknown
-
2006
- 2006-11-27 ZA ZA200609899A patent/ZA200609899B/xx unknown
- 2006-11-27 IL IL179630A patent/IL179630A/en active IP Right Grant
- 2006-12-28 NO NO20066041A patent/NO338624B1/no unknown
-
2007
- 2007-10-23 HK HK07111416.6A patent/HK1106136A1/xx unknown
-
2008
- 2008-06-30 HR HR20080307T patent/HRP20080307T3/hr unknown
- 2008-07-02 CY CY20081100696T patent/CY1110388T1/el unknown
-
2009
- 2009-10-20 CL CL2009001980A patent/CL2009001980A1/es unknown
-
2010
- 2010-03-08 US US12/719,221 patent/US20100168133A1/en not_active Abandoned
-
2012
- 2012-07-06 JP JP2012152373A patent/JP5675718B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080307T3 (hr) | Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove | |
| RS51730B (en) | HINOLINE DERIVATIVES FOR TREATMENT OF LATENT TUBERCULOSIS | |
| RS53065B (en) | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | |
| RS52431B (en) | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | |
| RS52808B (en) | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | |
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| JO2977B1 (en) | Conjulin derivatives acting as antibacterial agents | |
| EA200601363A1 (ru) | Замещённые хинолины и их применение в качестве микобактериальных ингибиторов | |
| JP2017513887A5 (hr) | ||
| RS52517B (en) | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | |
| AR054587A1 (es) | Derivados de quinolina antibacterianos | |
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| NO20080499L (no) | Kinolinderivater som antibakterielle midler | |
| HRP20110540T1 (hr) | Antibakterijski derivati kinolina | |
| EA200500802A1 (ru) | Лечение латентного туберкулёза | |
| MY151030A (en) | Quinoline derivatives as antibacterial agents |